It has been reported that the occurrence of immune-related adverse events (irAEs) in oncological patients treated with immune-checkpoint inhibitors (ICIs) may be associated with favorable clinical outcome. We reported the clinical correlation between irAEs and the efficacy of ICIs in a real-world cohort of metastatic renal cell cancer (mRCC) patients.
Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors / Paderi, Agnese; Giorgione, Roberta; Giommoni, Elisa; Mela, Marinella Micol; Rossi, Virginia; Doni, Laura; Minervini, Andrea; Carini, Marco; Pillozzi, Serena; Antonuzzo, Lorenzo. - In: CANCERS. - ISSN 2072-6694. - STAMPA. - 13:(2021), pp. 860.1-860.11. [10.3390/cancers13040860]
Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
Paderi, Agnese;Giorgione, Roberta;Giommoni, Elisa;Rossi, Virginia;Minervini, Andrea;Carini, Marco;Pillozzi, Serena;Antonuzzo, Lorenzo
2021
Abstract
It has been reported that the occurrence of immune-related adverse events (irAEs) in oncological patients treated with immune-checkpoint inhibitors (ICIs) may be associated with favorable clinical outcome. We reported the clinical correlation between irAEs and the efficacy of ICIs in a real-world cohort of metastatic renal cell cancer (mRCC) patients.
| File | Dimensione | Formato | |
|---|---|---|---|
|
cancers-13-00860 (1).pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Creative commons
Dimensione
479.23 kB
Formato
Adobe PDF
|
479.23 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
